Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors

β-lactamases are a major cause of rapidly emerging and spreading antibiotic resistance. Currently β-lactamase inhibitors (BLIs) in clinical use act only on Ambler Class A, C and some class D lactamases. The urgent need to identify new BLIs recently lead to FDA approval of boron-based compounds BLIs,...

Descripción completa

Detalles Bibliográficos
Autores principales: Perbandt, Markus, Werner, Nadine, Prester, Andreas, Rohde, Holger, Aepfelbacher, Martin, Hinrichs, Winfried, Betzel, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976068/
https://www.ncbi.nlm.nih.gov/pubmed/35365689
http://dx.doi.org/10.1038/s41598-022-09392-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976068/
https://www.ncbi.nlm.nih.gov/pubmed/35365689
http://dx.doi.org/10.1038/s41598-022-09392-6

Ejemplares similares